Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.

Payment Options